The added value of type I interferons to cytotoxic treatments of cancer

Cytokine and Growth Factor Reviews

Volumn 36, Issue , 2017, Pages 89-97

  Bracci, Laura ^a   Sistigu, Antonella ^b,c   Proietti, Enrico ^a   Moschella, Federica ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Chemotherapy; Immunogenicity; Radiotherapy; Type I interferon

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MICRORNA; NOTCH3 RECEPTOR; PROTEIN P53; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TOLL LIKE RECEPTOR 3; TRASTUZUMAB; TUMOR NECROSIS FACTOR; UBIQUITIN; UBIQUITIN SPECIFIC PEPTIDASE 18; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DNA DAMAGE RESPONSE; ENZYME ACTIVATION; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CELL DIFFERENTIATION; DRUG EFFECTS; GENETIC EPIGENESIS; IMMUNOLOGY; METABOLISM; MOUSE; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; EPIGENESIS, GENETIC; HUMANS; INTERFERON TYPE I; MICE; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 85021700370     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2017.06.008     Document Type: Short Survey

References (100)

1. Santini, S.M., Lapenta, C., Logozzi, M., Parlato, S., Spada, M., Di Pucchio, T., et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. 191 (2000), 1777–1788.
2. Moschella, F., Bisikirska, B., Maffei, A., Papadopoulos, K.P., Skerrett, D., Liu, Z., et al. Gene expression profiling and functional activity of human dendritic cells induced with IFN-alpha-2b: implications for cancer immunotherapy. Clin. Cancer Res. 9 (2003), 2022–2031.
3. Huber, J.P., Farrar, J.D., Regulation of effector and memory T-cell functions by type I interferon. Immunology 132 (2011), 466–474, 10.1111/j.1365-2567.2011.03412.x.
4. Paolini, R., Bernardini, G., Molfetta, R., Santoni, A., NK cells and interferons. Cytokine Growth Factor Rev. 26 (2015), 113–120, 10.1016/j.cytogfr.2014.11.003.
5. Trinchieri, G., Type I interferon: friend or foe?. J. Exp Med. 207 (2010), 2053–2063, 10.1084/jem.20101664.
6. Antonelli, G., Scagnolari, C., Moschella, F., Proietti, E., Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use. Cytokine Growth Factor Rev. 26 (2015), 121–131, 10.1016/j.cytogfr.2014.12.006.
7. Platanias, L.C., Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5 (2005), 375–386, 10.1038/nri1604.
8. Arico, E., Belardelli, F., Interferon-alpha as antiviral and antitumor vaccine adjuvants: mechanisms of action and response signature. J. Interferon Cytokine Res. 32 (2012), 235–247, 10.1089/jir.2011.0077.
9. Rizza, P., Moretti, F., Capone, I., Belardelli, F., Role of type I interferon in inducing a protective immune response: perspectives for clinical applications. Cytokine Growth Factor Rev. 26 (2015), 195–201, 10.1016/j.cytogfr.2014.10.002.
10. Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M.J., Kroemer, G., Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15 (2015), 405–414, 10.1038/nri3845.
11. Belardelli, F., Gresser, I., Maury, C., Maunoury, M.T., Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. I. Int. J. Cancer 30 (1982), 813–820.
12. Gresser, I., Maury, C., Carnaud, C., De Maeyer, E., Maunoury, M.T., Belardelli, F., Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend erythroleukemia cells. VIII. Role of the immune system in the inhibition of visceral metastases. Int. J. Cancer 46 (1990), 468–474.
13. Belardelli, F., Gresser, I., The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol. Today 17 (1996), 369–372, 10.1016/0167-5699(96)10027-X.
14. Ferrantini, M., Belardelli, F., Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications. Semin. Cancer Biol. 10 (2000), 145–157, 10.1006/scbi.2000.0333.
15. Narumi, K., Udagawa, T., Kondoh, A., Kobayashi, A., Hara, H., Ikarashi, Y., et al. In vivo delivery of interferon-alpha gene enhances tumor immunity and suppresses immunotolerance in reconstituted lymphopenic hosts. Gene Ther. 19 (2012), 34–48, 10.1038/gt.2011.73.
16. Escobar, G., Moi, D., Ranghetti, A., Ozkal-Baydin, P., Squadrito, M.L., Kajaste-Rudnitski, A., et al. Genetic engineering of hematopoiesis for targeted IFN-alpha delivery inhibits breast cancer progression. Sci. Transl. Med., 6, 2014, 10.1126/scitranslmed.3006353 (217ra3).
17. Gresser, I., Belardelli, F., Maury, C., Maunoury, M.T., Tovey, M.G., Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors. J. Exp. Med. 158 (1983), 2095–2107.
18. Picaud, S., Bardot, B., De Maeyer, E., Seif, I., Enhanced tumor development in mice lacking a functional type I interferon receptor. J. Interferon Cytokine Res. 22 (2002), 457–462, 10.1089/10799900252952244.
19. Dunn, G.P., Koebel, C.M., Schreiber, R.D., Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6 (2006), 836–848.
20. Diamond, M.S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G.P., Archambault, J.M., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208 (2011), 1989–2003, 10.1084/jem.20101158.
21. Wenzel, J., Bekisch, B., Uerlich, M., Haller, O., Bieber, T., Tuting, T., Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. Am. J. Clin. Pathol. 124 (2005), 37–48, 10.1309/4EJ9KL7CGDENVVLE.
22. Bidwell, B.N., Slaney, C.Y., Withana, N.P., Forster, S., Cao, Y., Loi, S., et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 18 (2012), 1224–1231, 10.1038/nm.2830.
23. Derer, A., Frey, B., Fietkau, R., Gaipl, U.S., Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors. Cancer Immunol. Immunother. 65 (2016), 779–786, 10.1007/s00262-015-1771-8.
24. Deng, L., Liang, H., Fu, S., Weichselbaum, R.R., Fu, Y.X., From DNA damage to nucleic acid sensing: a strategy to enhance radiation therapy. Clin. Cancer Res. 22 (2016), 20–25, 10.1158/1078-0432.CCR-14-3110.
25. Mole, R.H., Whole body irradiation; radiobiology or medicine?. Br J. Radiol. 26 (1953), 234–241, 10.1259/0007-1285-26-305-234.
26. Demaria, S., Ng, B., Devitt, M.L., Babb, J.S., Kawashima, N., Liebes, L., et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004), 862–870, 10.1016/j.ijrobp.2003.09.012.
27. Postow, M.A., Callahan, M.K., Barker, C.A., Yamada, Y., Yuan, J., Kitano, S., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366 (2012), 925–931, 10.1056/NEJMoa1112824.
28. Jurin, M., Suit, H.D., In vivo and in vitro studies of the influence of the immune status of C3Hf-Bu mice on the effectiveness of local irradiation of a methylcholanthrene-induced fibrosarcoma. Cancer Res. 32 (1972), 2201–2211.
29. McBride, W.H., Chiang, C.S., Olson, J.L., Wang, C.C., Hong, J.H., Pajonk, F., et al. A sense of danger from radiation. Radiat. Res. 162 (2004), 1–19.
30. Kono, H., Rock, K.L., How dying cells alert the immune system to danger. Nat. Rev. Immunol. 8 (2008), 279–289, 10.1038/nri2215.
31. Hallahan, D.E., Spriggs, D.R., Beckett, M.A., Kufe, D.W., Weichselbaum, R.R., Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc. Natl. Acad. Sci. U S A 86 (1989), 10104–10107.
32. Zhang, J.S., Nakatsugawa, S., Niwa, O., Ju, G.Z., Liu, S.Z., Ionizing radiation-induced IL-1 alpha, IL-6 and GM-CSF production by human lung cancer cells. Chin. Med. J. (Engl.) 107 (1994), 653–657.
33. Ishihara, H., Tsuneoka, K., Dimchev, A.B., Shikita, M., Induction of the expression of the interleukin-1 beta gene in mouse spleen by ionizing radiation. Radiat. Res. 133 (1993), 321–326.
34. Burnette, B.C., Liang, H., Lee, Y., Chlewicki, L., Khodarev, N.N., Weichselbaum, R.R., et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res. 71 (2011), 2488–2496, 10.1158/0008-5472.CAN-10-2820.
35. Lugade, A.A., Moran, J.P., Gerber, S.A., Rose, R.C., Frelinger, J.G., Lord, E.M., Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J.Immunol 174 (2005), 7516–7523.
36. Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41 (2014), 843–852, 10.1016/j.immuni.2014.10.019.
37. Rodriguez-Ruiz, M.E., Rodriguez, I., Garasa, S., Barbes, B., Solorzano, J.L., Perez-Gracia, J.L., et al. Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming. Cancer Res. 76 (2016), 5994–6005, 10.1158/0008-5472.CAN-16-0549.
38. Lim, J.Y., Gerber, S.A., Murphy, S.P., Lord, E.M., Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol. Immunother. 63 (2014), 259–271, 10.1007/s00262-013-1506-7.
39. Wu, J., Chen, Z.J., Innate immune sensing and signaling of cytosolic nucleic acids. Annu. Rev. Immunol. 32 (2014), 461–488, 10.1146/annurev-immunol-032713-120156.
40. Chatzinikolaou, G., Karakasilioti, I., Garinis, G.A., DNA damage and innate immunity: links and trade-offs. Trends Immunol. 35 (2014), 429–435, 10.1016/j.it.2014.06.003.
41. Harrison, J.C., Haber, J.E., Surviving the breakup: the DNA damage checkpoint. Annu. Rev. Genet. 40 (2006), 209–235, 10.1146/annurev.genet.40.051206.105231.
42. Klarquist, J., Hennies, C.M., Lehn, M.A., Reboulet, R.A., Feau, S., Janssen, E.M., STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells. J. Immunol. 193 (2014), 6124–6134, 10.4049/jimmunol.1401869.
43. Ishikawa, H., Ma, Z., Barber, G.N., STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461 (2009), 788–792, 10.1038/nature08476.
44. Ahn, J., Gutman, D., Saijo, S., Barber, G.N., STING manifests self DNA-dependent inflammatory disease. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 19386–19391, 10.1073/pnas.1215006109.
45. Corrales, L., Gajewski, T.F., Molecular pathways targeting the stimulator of interferon genes (STING) in the immunotherapy of cancer. Clin. Cancer Res. 21 (2015), 4774–4779, 10.1158/1078-0432.CCR-15-1362.
46. Keating, S.E., Baran, M., Bowie, A.G., Cytosolic DNA sensors regulating type I interferon induction. Trends Immunol. 32 (2011), 574–581, 10.1016/j.it.2011.08.004.
47. Sun, L., Wu, J., Du, F., Chen, X., Chen, Z.J., Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339 (2013), 786–791, 10.1126/science.1232458.
48. Hartlova, A., Erttmann, S.F., Raffi, F.A., Schmalz, A.M., Resch, U., Anugula, S., et al. DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. Immunity 42 (2015), 332–343, 10.1016/j.immuni.2015.01.012.
49. Ranoa, D.R., Parekh, A.D., Pitroda, S.P., Huang, X., Darga, T., Wong, A.C., et al. Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. Oncotarget 7 (2016), 26496–26515, 10.18632/oncotarget.8420.
50. Brzostek-Racine, S., Gordon, C., Van Scoy, S., Reich, N.C., The DNA damage response induces IFN. J. Immunol. 187 (2011), 5336–5345, 10.4049/jimmunol.1100040.
51. Shen, Y.J., Le Bert, N., Chitre, A.A., Koo, C.X., Nga, X.H., Ho, S.S., et al. Genome-derived cytosolic DNA mediates type I interferon-dependent rejection of B cell lymphoma cells. Cell Rep. 11 (2015), 460–473, 10.1016/j.celrep.2015.03.041.
52. Luthra, P., Aguirre, S., Yen, B.C., Pietzsch, C.A., Sanchez-Aparicio, M.T., Tigabu, B., et al. Topoisomerase II inhibitors induce DNA damage-dependent interferon responses circumventing ebola virus immune evasion. MBio, 8, 2017, 10.1128/mBio.00368-17.
53. Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L., Kroemer, G., Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17 (2017), 97–111, 10.1038/nri.2016.107.
54. Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D.P., Adam, J., et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20 (2014), 1301–1309, 10.1038/nm.3708.
55. Gaston, J., Cheradame, L., Yvonnet, V., Deas, O., Poupon, M.F., Judde, J.G., et al. Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents. Oncotarget 7 (2016), 77205–77224, 10.18632/oncotarget.12858.
56. Bracci, L., Proietti, E., Belardelli, F., IFN-alpha and novel strategies of combination therapy for cancer. Ann. N. Y. Acad. Sci. 1112 (2007), 256–268, 10.1196/annals.1415.030.
57. Proietti, E., Moschella, F., Capone, I., Belardelli, F., Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy. Mol. Oncol. 6 (2012), 1–14, 10.1016/j.molonc.2011.11.005.
58. Moschella, F., Proietti, E., Capone, I., Belardelli, F., Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Ann. N. Y. Acad. Sci. 1194 (2010), 169–178, 10.1111/j.1749-6632.2010.05464.x.
59. Schiavoni, G., Mattei, F., Di Pucchio, T., Santini, S.M., Bracci, L., Belardelli, F., et al. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95 (2000), 2024–2030.
60. Salem, M.L., Kadima, A.N., El-Naggar, S.A., Rubinstein, M.P., Chen, Y., Gillanders, W.E., et al. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J. Immunother. 30 (2007), 40–53, 10.1097/01.cji.0000211311.28739.e3.
61. Bracci, L., Moschella, F., Sestili, P., La Sorsa, V., Valentini, M., Canini, I., et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin. Cancer Res. 13 (2007), 644–653, 10.1158/1078-0432.CCR-06-1209.
62. Schiavoni, G., Sistigu, A., Valentini, M., Mattei, F., Sestili, P., Spadaro, F., et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 71 (2011), 768–778.
63. Salem, M.L., Diaz-Montero, C.M., Al-Khami, A.A., El-Naggar, S.A., Naga, O., Montero, A.J., et al. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). J. Immunol. 182 (2009), 2030–2040.
64. Moschella, F., Valentini, M., Arico, E., Macchia, I., Sestili, P., D'Urso, M.T., et al. Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide. Cancer Res. 71 (2011), 3528–3539, 10.1158/0008-5472.CAN-10-4523.
65. Moschella, F., Torelli, G.F., Valentini, M., Urbani, F., Buccione, C., Petrucci, M.T., et al. Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapy. Clin. Cancer Res. 19 (2013), 4249–4261, 10.1158/1078-0432.CCR-12-3666.
66. Ziccheddu, G., Proietti, E., Moschella, F., The Janus face of cyclophosphamide: a sterile inflammatory response that potentiates cancer immunotherapy. Oncoimmunology, 2, 2013, e25789, 10.4161/onci.25789.
67. Nistico, P., Capone, I., Palermo, B., Del Bello, D., Ferraresi, V., Moschella, F., et al. Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int. J. Cancer 124 (2009), 130–139, 10.1002/ijc.23886.
68. Chiappinelli, K.B., Strissel, P.L., Desrichard, A., Li, H., Henke, C., Akman, B., et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162 (2015), 974–986, 10.1016/j.cell.2015.07.011.
69. Roulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S.Y., et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162 (2015), 961–973, 10.1016/j.cell.2015.07.056.
70. Stagg, J., Loi, S., Divisekera, U., Ngiow, S.F., Duret, H., Yagita, H., et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 7142–7147, 10.1073/pnas.1016569108.
71. Minn, A.J., Interferons and the immunogenic effects of cancer therapy. Trends Immunol. 36 (2015), 725–737, 10.1016/j.it.2015.09.007.
72. Meissl, K., Macho-Maschler, S., Muller, M., Strobl, B., The good and the bad faces of STAT1 in solid tumours. Cytokine 89 (2017), 12–20, 10.1016/j.cyto.2015.11.011.
73. Teijaro, J.R., Ng, C., Lee, A.M., Sullivan, B.M., Sheehan, K.C., Welch, M., et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340 (2013), 207–211, 10.1126/science.1235214.
74. Wilson, E.B., Yamada, D.H., Elsaesser, H., Herskovitz, J., Deng, J., Cheng, G., et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340 (2013), 202–207, 10.1126/science.1235208.
75. Khodarev, N.N., Beckett, M., Labay, E., Darga, T., Roizman, B., Weichselbaum, R.R., STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 1714–1719, 10.1073/pnas.0308102100.
76. Khodarev, N.N., Minn, A.J., Efimova, E.V., Darga, T.E., Labay, E., Beckett, M., et al. Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. Cancer Res. 67 (2007), 9214–9220, 10.1158/0008-5472.CAN-07-1019.
77. Zhan, J.F., Chen, L.H., Yuan, Y.W., Xie, G.Z., Sun, A.M., Liu, Y., et al. STAT1 promotes radioresistance of CD44(+)/CD24(-/low) cells in breast cancer. Exp. Biol. Med. (Maywood) 236 (2011), 418–422, 10.1258/ebm.2011.010287.
78. Weichselbaum, R.R., Ishwaran, H., Yoon, T., Nuyten, D.S., Baker, S.W., Khodarev, N., et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 18490–18495, 10.1073/pnas.0809242105.
79. Rickardson, L., Fryknas, M., Dhar, S., Lovborg, H., Gullbo, J., Rydaker, M., et al. Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br. J. Cancer 93 (2005), 483–492, 10.1038/sj.bjc.6602699.
80. Roberts, D., Schick, J., Conway, S., Biade, S., Laub, P.B., Stevenson, J.P., et al. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br. J. Cancer 92 (2005), 1149–1158, 10.1038/sj.bjc.6602447.
81. Boelens, M.C., Wu, T.J., Nabet, B.Y., Xu, B., Qiu, Y., Yoon, T., et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell 159 (2014), 499–513, 10.1016/j.cell.2014.09.051.
82. Cheon, H., Stark, G.R., Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 9373–9378, 10.1073/pnas.0903487106.
83. Cheon, H., Holvey-Bates, E.G., Schoggins, J.W., Forster, S., Hertzog, P., Imanaka, N., et al. IFNbeta-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J. 32 (2013), 2751–2763, 10.1038/emboj.2013.203.
84. Ivashkiv, L.B., Donlin, L.T., Regulation of type I interferon responses. Nat. Rev. Immunol. 14 (2014), 36–49, 10.1038/nri3581.
85. Blank, C., Mackensen, A., Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol. Immunother. 56 (2007), 739–745, 10.1007/s00262-006-0272-1.
86. Lucarini, V., Buccione, C., Ziccheddu, G., Peschiaroli, F., Sestili, P., Puglisi, R., et al. Combining type I interferons and 5-Aza-2'-deoxycitidine to improve anti-tumor response against melanoma. J. Invest. Dermatol. 137 (2017), 159–169, 10.1016/j.jid.2016.08.024.
87. Twyman-Saint Victor, C., Rech, A.J., Maity, A., Rengan, R., Pauken, K.E., Stelekati, E., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520 (2015), 373–377, 10.1038/nature14292.
88. Benci, J.L., Xu, B., Qiu, Y., Wu, T.J., Dada, H., Twyman-Saint Victor, C., et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167 (2016), 1540–1554, 10.1016/j.cell.2016.11.022 (e12).
89. Bald, T., Landsberg, J., Lopez-Ramos, D., Renn, M., Glodde, N., Jansen, P., et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 4 (2014), 674–687, 10.1158/2159-8290.CD-13-0458.
90. Matarrese, P., Di Biase, L., Santodonato, L., Straface, E., Mecchia, M., Ascione, B., et al. Type I interferon gene transfer sensitizes melanoma cells to apoptosis via a target activity on mitochondrial function. Am. J. Pathol. 160 (2002), 1507–1520, 10.1016/S0002-9440(10)62577-1.
91. Manara, M.C., Serra, M., Benini, S., Picci, P., Scotlandi, K., Effectiveness of Type I interferons in the treatment of multidrug resistant osteosarcoma cells. Int. J. Oncol. 24 (2004), 365–372.
92. Dean, M., Fojo, T., Bates, S., Tumour stem cells and drug resistance. Nat. Rev. Cancer 5 (2005), 275–284, 10.1038/nrc1590.
93. Zhu, Y., Karakhanova, S., Huang, X., Deng, S.P., Werner, J., Bazhin, A.V., Influence of interferon-alpha on the expression of the cancer stem cell markers in pancreatic carcinoma cells. Exp. Cell Res. 324 (2014), 146–156, 10.1016/j.yexcr.2014.03.020.
94. Kayo, H., Yamazaki, H., Nishida, H., Dang, N.H., Morimoto, C., Stem cell properties and the side population cells as a target for interferon-alpha in adult T-cell leukemia/lymphoma. Biochem. Biophys. Res. Commun. 364 (2007), 808–814, 10.1016/j.bbrc.2007.10.070.
95. Motawi, T.K., El-Boghdady, N.A., El-Sayed, A.M., Helmy, H.S., Comparative study of the effects of PEGylated interferon-alpha2a versus 5-fluorouracil on cancer stem cells in a rat model of hepatocellular carcinoma. Tumour Biol. 37 (2016), 1617–1625, 10.1007/s13277-015-3920-2.
96. Hayashi, T., Ding, Q., Kuwahata, T., Maeda, K., Miyazaki, Y., Matsubara, S., et al. Interferon-alpha modulates the chemosensitivity of CD133-expressing pancreatic cancer cells to gemcitabine. Cancer Sci. 103 (2012), 889–896, 10.1111/j.1349-7006.2012.02235.x.
97. Buoncervello, M., Romagnoli, G., Buccarelli, M., Fragale, A., Toschi, E., Parlato, S., et al. IFN-alpha potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer. Oncotarget 7 (2016), 26361–26373, 10.18632/oncotarget.8379.
98. Essers, M.A., Offner, S., Blanco-Bose, W.E., Waibler, Z., Kalinke, U., Duchosal, M.A., et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 458 (2009), 904–908.
99. Trumpp, A., Essers, M., Wilson, A., Awakening dormant haematopoietic stem cells. Nat. Rev. Immunol. 10 (2010), 201–209, 10.1038/nri2726.
100. Takeuchi, A., Eto, M., Tatsugami, K., Yamada, H., Oki, T., Kiyoshima, K., et al. Mechanism of synergistic antitumor effect of sorafenib and interferon-alpha on treatment of renal cell carcinoma. J. Urol. 184 (2010), 2549–2556, 10.1016/j.juro.2010.07.033.